Global Peripheral Neuritis Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Anti-Depressants, Tricyclic, Selective Serotonin/Norepinephrine Reuptake Inhibitors, Serotonin Reuptake Inhibitors, Anticonvulsants, Local Anesthesia, Analgesics, NSAID, Opioid, Steroids, and Others.

By Application;

Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Others.

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn870847593 Published Date: February, 2025 Updated Date: March, 2025

Introduction

Global Peripheral Neuritis Treatment Market (USD Million), 2021 - 2031

In the year 2024, the Global Peripheral Neuritis Treatment Market was valued at USD 1118.12 million. The size of this market is expected to increase to USD 1681.24 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.0%.

The global peripheral neuritis treatment market is driven by the rising prevalence of peripheral neuropathy, which can be caused by various factors such as diabetes, infections, alcohol abuse, and autoimmune diseases. The increasing global diabetic population and aging demographics are significant contributors to the growing demand for peripheral neuritis treatments. As the disease often leads to symptoms like pain, numbness, and muscle weakness, patients seek effective treatment options to manage these debilitating symptoms. This trend is further supported by advancements in treatment methodologies, including pharmacological interventions such as pain management medications, anti-inflammatory drugs, and nerve growth factor-based therapies.

Treatment options for peripheral neuritis include pharmacological approaches such as analgesics, corticosteroids, and anticonvulsants, as well as non-pharmacological treatments such as physical therapy and lifestyle modifications. The market is also witnessing the development of more advanced treatment modalities, including nerve regeneration therapies, targeted pain relief treatments, and gene therapies. Moreover, medical devices like transcutaneous electrical nerve stimulation (TENS) units are also gaining traction in the market. These innovations are aimed at improving the overall quality of life for patients and reducing the long-term effects of peripheral neuritis.

In terms of geography, the global market is concentrated in North America and Europe, where advanced healthcare infrastructure, high awareness levels, and strong reimbursement policies lead to a higher adoption of treatment options. However, emerging markets in Asia-Pacific and Latin America are experiencing significant growth due to improving healthcare access, rising healthcare expenditures, and increasing awareness about the condition. As the healthcare landscape evolves, the demand for peripheral neuritis treatments is expected to increase globally, with a focus on more personalized and effective therapeutic options tailored to individual patient needs. The increasing focus on early diagnosis and prevention will also boost the market in the coming years.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Application
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Global Peripheral Neuritis Treatment Market Trends
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing prevalence of diabetes
        2. Aging population
        3. Advances in pharmaceutical research
        4. Technological advancements in diagnostics
      2. Restraints
        1. Limited efficacy of current treatments
        2. High cost of novel therapies
        3. Regulatory challenges and approval timelines
        4. Side effects associated with medications
      3. Opportunities
        1. Development of targeted therapies
        2. Expansion in emerging markets
        3. Personalized medicine approaches
        4. Collaborations and partnerships in research
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Global Peripheral Neuritis Treatment Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Anti-Depressants
      2. Tricyclic
      3. Selective Serotonin/Norepinephrine Reuptake Inhibitors
      4. Serotonin Reuptake Inhibitors
      5. Anticonvulsants
      6. Local Anesthesia
      7. Analgesics
      8. NSAID
      9. Opioid
      10. Steroids
      11. Others
    2. Global Peripheral Neuritis Treatment Market, By Application, 2021 - 2031 (USD Million)
      1. Diabetic Peripheral Neuropathy
      2. Chemotherapy-Induced Peripheral Neuropathy
      3. Idiopathic Peripheral Neuropathy
      4. Others
    3. Global Peripheral Neuritis Treatment Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Drug Stores
      4. Online Pharmacies
    4. Global Peripheral Neuritis Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Pfizer Inc
      2. Assertio Therapeutics Inc
      3. Eli Lilly and Company
      4. WinSanTor Inc
  7. Analyst Views
  8. Future Outlook of the Market